Lantern Pharma (LTRN) Research & Development (2020 - 2026)
Lantern Pharma's (LTRN) quarterly Research & Development came in at $1.7 million in Q1 2026, down 47.15% YoY from $3.3 million in Q1 2025, and down 37.16% on a QoQ basis from $2.7 million in Q4 2025.
Lantern Pharma (LTRN) Research & Development (2020 - 2026) Analysis & Trends
Lantern Pharma (LTRN) has 7 years of Research & Development data on file, last reported at $1.7 million in Q1 2026.
- Quarterly Research & Development fell 47.15% year-over-year to $1.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.0 million (down 34.11% YoY) and the FY2025 annual result came in at $11.5 million, down 28.6% from the prior year.
- Research & Development fell to $1.7 million in Q1 2026, from $2.7 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $4.3 million in Q4 2024 to a low of $702296.0 in Q3 2022.
- A 5-year average of $2.9 million and a median of $3.0 million in 2022 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2022 — Research & Development sank 76.31% — and 2023, when it soared 214.67%.
- Tracing LTRN's Research & Development over 5 years: stood at $2.3 million in 2022, then soared by 58.7% to $3.6 million in 2023, then rose by 19.49% to $4.3 million in 2024, then plunged by 35.71% to $2.7 million in 2025, then sank by 37.16% to $1.7 million in 2026.
- The last three Research & Development figures came in at $1.7 million (Q1 2026), $2.7 million (Q4 2025), and $2.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Lantern Pharma | 26.11 Mn | 26.11 Mn | - | 1.72 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.72 Mn |
| Dec 31, 2025 | 2.74 Mn |
| Sep 30, 2025 | 2.44 Mn |
| Jun 30, 2025 | 3.07 Mn |
| Mar 31, 2025 | 3.26 Mn |
| Dec 31, 2024 | 4.27 Mn |
| Sep 30, 2024 | 3.72 Mn |
| Jun 30, 2024 | 3.89 Mn |
| Mar 31, 2024 | 4.25 Mn |
| Dec 31, 2023 | 3.57 Mn |
| Sep 30, 2023 | 2.21 Mn |
| Jun 30, 2023 | 3.56 Mn |
| Mar 31, 2023 | 2.55 Mn |
| Dec 31, 2022 | 2.25 Mn |
| Sep 30, 2022 | 702,296.00 |
| Jun 30, 2022 | 2.99 Mn |
| Mar 31, 2022 | 2.66 Mn |
| Dec 31, 2021 | 2.16 Mn |
| Sep 30, 2021 | 2.96 Mn |
| Jun 30, 2021 | 1.16 Mn |